{"id": "xKK589QAAAAJ", "citedby": 35402, "citedby5y": 11905, "hindex": 50, "hindex5y": 41, "i10index": 53, "i10index5y": 49, "coauthors": [], "name": "C. Kent Osborne", "affiliation": "Director/Professor, Duncan Cancer Center, Baylor College of Medicine", "interests": ["Breast Cancer", "Cancer", "Oncology", "Cancer Research"], "cites_per_year": {"1990": 93, "1991": 113, "1992": 121, "1993": 179, "1994": 229, "1995": 282, "1996": 299, "1997": 369, "1998": 385, "1999": 516, "2000": 611, "2001": 727, "2002": 757, "2003": 767, "2004": 977, "2005": 1340, "2006": 1440, "2007": 1279, "2008": 1450, "2009": 1425, "2010": 1584, "2011": 1691, "2012": 1875, "2013": 2015, "2014": 2172, "2015": 2391, "2016": 2477, "2017": 2354, "2018": 2075, "2019": 1872, "2020": 713}, "publications": [{"bib": {"title": "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in \u2026", "year": "2010"}, "source": "citations", "id_citations": "xKK589QAAAAJ:YTuZlYwrTOUC", "citedby": "2590"}, {"bib": {"title": "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", "year": "2013"}, "source": "citations", "id_citations": "xKK589QAAAAJ:2vr6o8x5NLkC", "citedby": "2426"}, {"bib": {"title": "Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer", "year": "1999"}, "source": "citations", "id_citations": "xKK589QAAAAJ:t-hv7AR41mYC", "citedby": "2059"}, {"bib": {"title": "Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy", "year": "2008"}, "source": "citations", "id_citations": "xKK589QAAAAJ:LGlY6t8CeOMC", "citedby": "1753"}, {"bib": {"title": "Tamoxifen in the treatment of breast cancer", "year": "1998"}, "source": "citations", "id_citations": "xKK589QAAAAJ:oPLKW5k6eA4C", "citedby": "1362"}, {"bib": {"title": "Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015", "year": "2015"}, "source": "citations", "id_citations": "xKK589QAAAAJ:9DLIHnF0jcYC", "citedby": "1312"}, {"bib": {"title": "Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2\u2013positive breast cancer", "year": "2004"}, "source": "citations", "id_citations": "xKK589QAAAAJ:hQUaER0FWQ4C", "citedby": "1276"}, {"bib": {"title": "Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a \u2026", "year": "2010"}, "source": "citations", "id_citations": "xKK589QAAAAJ:jtI9f0ekYq0C", "citedby": "1186"}, {"bib": {"title": "Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer", "year": "2003"}, "source": "citations", "id_citations": "xKK589QAAAAJ:_AeoHAGD03cC", "citedby": "981"}, {"bib": {"title": "Diseases of the Breast", "year": "2012"}, "source": "citations", "id_citations": "xKK589QAAAAJ:X0DADzN9RKwC", "citedby": "935"}, {"bib": {"title": "Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer", "year": "2003"}, "source": "citations", "id_citations": "xKK589QAAAAJ:TaaCk18tZOkC", "citedby": "909"}, {"bib": {"title": "Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu", "year": "1992"}, "source": "citations", "id_citations": "xKK589QAAAAJ:nPT8s1NX_-sC", "citedby": "899"}, {"bib": {"title": "Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer", "year": "1993"}, "source": "citations", "id_citations": "xKK589QAAAAJ:zUl2_INMlC4C", "citedby": "882"}, {"bib": {"title": "The value of estrogen and progesterone receptors in the treatment of breast cancer", "year": "1980"}, "source": "citations", "id_citations": "xKK589QAAAAJ:s85pQhAUCrAC", "citedby": "866"}, {"bib": {"title": "Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases", "year": "2003"}, "source": "citations", "id_citations": "xKK589QAAAAJ:z8nqeaKD1nsC", "citedby": "803"}, {"bib": {"title": "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes", "year": "1998"}, "source": "citations", "id_citations": "xKK589QAAAAJ:LK8CI43ZvvMC", "citedby": "781"}, {"bib": {"title": "Treatment of HER2-positive breast cancer: current status and future perspectives", "year": "2012"}, "source": "citations", "id_citations": "xKK589QAAAAJ:R-LXmdHK_14C", "citedby": "719"}, {"bib": {"title": "HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.", "year": "1992"}, "source": "citations", "id_citations": "xKK589QAAAAJ:pQTOvowfQioC", "citedby": "580"}, {"bib": {"title": "Steroid hormone receptors in breast cancer management", "year": "1998"}, "source": "citations", "id_citations": "xKK589QAAAAJ:nqdriD65xNoC", "citedby": "558"}, {"bib": {"title": "Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice", "year": "1985"}, "source": "citations", "id_citations": "xKK589QAAAAJ:lYAcb2jw7qUC", "citedby": "512"}, {"bib": {"title": "Estrogen receptor\u2013positive, progesterone receptor\u2013negative breast cancer: association with growth factor receptor expression and tamoxifen resistance", "year": "2005"}, "source": "citations", "id_citations": "xKK589QAAAAJ:QVtou7C4vgoC", "citedby": "511"}, {"bib": {"title": "ICI 182,780 (Faslodex\u2122) development of a novel,\u201cpure\u201d antiestrogen", "year": "2000"}, "source": "citations", "id_citations": "xKK589QAAAAJ:c_xDhezhKKUC", "citedby": "509"}, {"bib": {"title": "Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance", "year": "2008"}, "source": "citations", "id_citations": "xKK589QAAAAJ:Og1tA8FjbJAC", "citedby": "503"}, {"bib": {"title": "Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase", "year": "2005"}, "source": "citations", "id_citations": "xKK589QAAAAJ:wLxue7F8ec0C", "citedby": "498"}, {"bib": {"title": "Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer", "year": "2005"}, "source": "citations", "id_citations": "xKK589QAAAAJ:JWITY9-sCbMC", "citedby": "489"}, {"bib": {"title": "Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function", "year": "2008"}, "source": "citations", "id_citations": "xKK589QAAAAJ:wUn16MOA3RoC", "citedby": "473"}, {"bib": {"title": "Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer", "year": "1992"}, "source": "citations", "id_citations": "xKK589QAAAAJ:37UQlXuwjP4C", "citedby": "467"}, {"bib": {"title": "Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational \u2026", "year": "2004"}, "source": "citations", "id_citations": "xKK589QAAAAJ:ijdKiLOsEJMC", "citedby": "465"}, {"bib": {"title": "Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy", "year": "2005"}, "source": "citations", "id_citations": "xKK589QAAAAJ:qmtmRrLr0tkC", "citedby": "461"}, {"bib": {"title": "Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.", "year": "1987"}, "source": "citations", "id_citations": "xKK589QAAAAJ:Ic1VZgkJnDsC", "citedby": "459"}, {"bib": {"title": "Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States", "year": "1994"}, "source": "citations", "id_citations": "xKK589QAAAAJ:c59VksA5Vz4C", "citedby": "458"}, {"bib": {"title": "Selective estrogen receptor modulators: structure, function, and clinical use", "year": "2000"}, "source": "citations", "id_citations": "xKK589QAAAAJ:OzeSX8-yOCQC", "citedby": "453"}, {"bib": {"title": "Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance", "year": "2004"}, "source": "citations", "id_citations": "xKK589QAAAAJ:naSTrk-c4S8C", "citedby": "452"}, {"bib": {"title": "Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer", "year": "1995"}, "source": "citations", "id_citations": "xKK589QAAAAJ:dAp6zn-oMfAC", "citedby": "419"}, {"bib": {"title": "Aberrant subcellular localization of BRCA1 in breast cancer", "year": "1995"}, "source": "citations", "id_citations": "xKK589QAAAAJ:jmjb1lOE9QIC", "citedby": "418"}, {"bib": {"title": "Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.", "year": "1984"}, "source": "citations", "id_citations": "xKK589QAAAAJ:m92CDrhVnKEC", "citedby": "410"}, {"bib": {"title": "Estrogen-receptor biology: continuing progress and therapeutic implications", "year": "2005"}, "source": "citations", "id_citations": "xKK589QAAAAJ:eI34FqJmdUoC", "citedby": "408"}, {"bib": {"title": "Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials", "year": "2003"}, "source": "citations", "id_citations": "xKK589QAAAAJ:iyewoVqAXLQC", "citedby": "406"}, {"bib": {"title": "Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response", "year": "2003"}, "source": "citations", "id_citations": "xKK589QAAAAJ:AZju0d2GQJ0C", "citedby": "402"}, {"bib": {"title": "Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo", "year": "1999"}, "source": "citations", "id_citations": "xKK589QAAAAJ:yY3RG6sOEgwC", "citedby": "389"}, {"bib": {"title": "Estrogen receptor (ER) and progesterone receptor (PgR), by ligand\u2010binding assay compared with ER, PgR and pS2, by immuno\u2010histochemistry in predicting response to tamoxifen in \u2026", "year": "2000"}, "source": "citations", "id_citations": "xKK589QAAAAJ:sfnaS5RM6jYC", "citedby": "387"}, {"bib": {"title": "Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci", "year": "1998"}, "source": "citations", "id_citations": "xKK589QAAAAJ:BOlwja0KXvYC", "citedby": "377"}, {"bib": {"title": "Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer.", "year": "1995"}, "source": "citations", "id_citations": "xKK589QAAAAJ:sJPMR1oEGYQC", "citedby": "351"}, {"bib": {"title": "Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase", "year": "1983"}, "source": "citations", "id_citations": "xKK589QAAAAJ:ji7lAbPyDbYC", "citedby": "327"}, {"bib": {"title": "Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor", "year": "1989"}, "source": "citations", "id_citations": "xKK589QAAAAJ:m4fbC6XIj1kC", "citedby": "325"}, {"bib": {"title": "HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.", "year": "1998"}, "source": "citations", "id_citations": "xKK589QAAAAJ:wSy_KLzO7YEC", "citedby": "322"}, {"bib": {"title": "Transforming growth factor \u03b2: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells", "year": "1988"}, "source": "citations", "id_citations": "xKK589QAAAAJ:4e5Qn2KL_jwC", "citedby": "311"}, {"bib": {"title": "Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroxytamoxifen", "year": "1991"}, "source": "citations", "id_citations": "xKK589QAAAAJ:4Yq6kJLCcecC", "citedby": "284"}, {"bib": {"title": "Molecular profiles of progesterone receptor loss in human breast tumors", "year": "2009"}, "source": "citations", "id_citations": "xKK589QAAAAJ:ymY9cBF3mdcC", "citedby": "95"}, {"bib": {"title": "Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients", "year": "1997"}, "source": "citations", "id_citations": "xKK589QAAAAJ:nPTYJWkExTIC", "citedby": "65"}, {"bib": {"title": "A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer", "year": "1991"}, "source": "citations", "id_citations": "xKK589QAAAAJ:M0leSnx2MbUC", "citedby": "50"}, {"bib": {"title": "Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study", "year": "1992"}, "source": "citations", "id_citations": "xKK589QAAAAJ:1r-w4gtu6w8C", "citedby": "35"}, {"bib": {"title": "Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer", "year": "2010"}, "source": "citations", "id_citations": "xKK589QAAAAJ:pYKElYtJMmwC", "citedby": "25"}, {"bib": {"title": "Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast \u2026", "year": "2013"}, "source": "citations", "id_citations": "xKK589QAAAAJ:WwIwg2wKZ0QC", "citedby": "7"}, {"bib": {"title": "Current trials and future directions of the Southwest oncology group breast cancer committee", "year": "1994"}, "source": "citations", "id_citations": "xKK589QAAAAJ:jlhcAiayVhoC", "citedby": "1"}, {"bib": {"title": "Overexpression of HER-2/neu and its relationship with oter prognostic factors change during the progression of in situ to invasive breast cancer", "year": "1992"}, "source": "citations", "id_citations": "xKK589QAAAAJ:n3vGvpFsckwC", "citedby": "1"}, {"bib": {"title": "Adjuvant therapy for stage II, estrogen receptor negative breast cancer", "year": "1981"}, "source": "citations", "id_citations": "xKK589QAAAAJ:hNSvKAmkeYkC", "citedby": "0"}]}